Diplomat Specialty Pharmacy to Provide Specialty Pharmacy Services for EYLEA™ (aflibercept) Injection
Diplomat Specialty Pharmacy, the nation’s largest independent specialty pharmacy in the nation, announced today it has received limited distribution rights from Regeneron for its new drug EYLEA™ (aflibercept) Injection.
On November 18, 2011, EYLEA (aflibercept) Injection was approved by the Food and Drug Administration and is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD). Macular degeneration is diagnosed as either dry (non-vascular) or wet (vascular) and is a leading cause of blindness in older adults. The wet form usually leads to more serious vision loss.
“EYLEA represents an important new therapy in the treatment of AMD,” said Phil Hagerman, president and CEO of Diplomat. “AMD is becoming more and more prevalent in Americans 60 years of age and older; Diplomat looks forward to providing services to help treat this growing population of patients to slow the progression of this disease.”
About Diplomat Specialty PharmacyMichigan-based Diplomat Specialty Pharmacy, founded in 1975, serves patients nationwide as the country’s largest privately held Specialty Pharmacy and focuses on complete medication management programs for patients with serious and chronic conditions. Diplomat’s business model creates unique partnerships around both distribution and services with industry stakeholders with Group Purchasing Organizations, Hospital systems, retail chains and managed markets, always focused on improving adherence and the patient experience.
How Oregon’s Death-Penalty Drugs Ended Up With a New York Firm
Since 1986, New York’s Devos, Ltd, has steadily built a business with an annual revenue of $32.2 million handling overstocked, expired, or recalled drugs on pharmacy shelves throughout the nation. Operating as Guaranteed Returns, Devos is the industry leader in a specialized business called reverse pharmaceutical distribution. Reverse pharmaceutical distribution comes out of the need to carefully navigate the minefield of state and federal regulations surrounding controlled substances, and the equally difficult task of complying with hundreds of manufacturers’ and wholesalers’ strict rules for properly returning or reselling goods that lose all value once improperly stored or tampered with.
After Oregon’s Department of Corrections (ODOC) got word of Governor John Kitzhaber’s November 2011 announcement that he’ll no longer enforce the state’s death penalty, its pharmacy unit rang up Guaranteed Returns, the reverse distributor of choice for most VA Hospitals. It’s unclear if the decision to return rather than destroy the drugs ever reached Governor Kitzhaber’s notice before being publicly reported in The Bend Bulletin on December 24. Once aware, the governor took no action and never acknowledged the glaring contradiction with his own recently announced stand against the death penalty, despite the fact that clamping down on America’s supply of these drugs is the crux of a new international strategy that puts pressure on death-penalty states.
Guaranteed Returns now possesses Oregon’s lethal cocktail mixers, the ODOC told me.
So deciding where to resell $18,000-worth of pentobarbital sodium, pancuronium bromide, and potassium chloride rests entirely with Guaranteed Returns and its CEO, Dean Volkes. Guaranteed Returns’s business model typically involves resale to a pharmaceutical wholesaler or return to the original manufacturer for those drugs with an applicable return policy. The company also incinerates drugs that are damaged, expired, or have no marketable value.
Guaranteed Returns has an opportunity to act responsibly where Oregon did not. Rather than laundering these drugs back to a manufacturer or wholesaler of the kind that saw no problem selling to Oregon’s Department of Corrections in the first place, the multi-million-dollar company can eat this $18,000 cost in the name of human rights and incinerate this supply of lethal injection medications. Alternatively, Guaranteed Returns can decide it will only sell to parties that will certify, in writing, that the drugs will not find their way into a death chamber.
New York carried out its last execution in 1963, and though capital punishment is still on the books, in 2008 its governor ordered the destruction of the remaining apparatus of death row and the death chamber. If Oregon’s Governor Kitzhaber has missed his chance to stop this outrage, New York’s Governor Andrew Cuomo is now in a position to fix things for him.
Governor Cuomo could ask New York-based pharmaceutical companies and distributors to certify that their medical products won’t land in the store rooms of government agencies who will use them to kill people. If these companies don’t heed such a warning, New York’s Division of Human Rights and its attorney general could serve the nation well by launching investigations into those Empire State corporations that mishandle controlled substances so grievously that they wind up stocking death-chamber drug cabinets.